However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86)
43 The review of studies included in this analysis also reveals a potential link between the use of GLP-1 RAs and a reduced risk of dementia in AD patients, as well as a lower risk of mortality in dementia patients
Ive been a leader in medical weight loss for over a decade and I am deeply aware of how helpful these drugs can be for patients struggling with obesity or weight management
Cardiovascular risk reduction, while present, follows a less linear relationship
Based on this assumption, Ile 12 could be replaced with Leu or Val and retain the same effect
Novo Nordisk, the company that makes semaglutide, says it's important for all patients to get this medicine and find it affordable